logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On April 28th, BEKE-W (02423) spent approximately $7 million to repurchase approximately 1.3291 million shares.

date
19:00 29/04/2026
avatar
GMT Eight
Beike -W (02423) announced on April 28, 2026 that it will spend approximately 7 million US dollars to repurchase about 132.91 million shares.
BEKE-W (02423) announced that it will repurchase approximately 1.3291 million shares at a cost of around $7 million on April 28, 2026.
Related Articles
HK Stock
Midea Group Co., Ltd (00300) had a first quarter attributable net profit of 12.675 billion yuan, an increase of 2.03% year-on-year.
HK Stock
MICROPORT NEURO (02172) spent approximately HK$1.0348 million to repurchase 100,000 shares on April 29th.
HK Stock
Hansoh Pharma (03692): B7-H3 targeted antibody-drug conjugate HS-20093 approved as breakthrough therapy for castration-resistant prostate cancer.
Midea Group Co., Ltd (00300) had a first quarter attributable net profit of 12.675 billion yuan, an increase of 2.03% year-on-year.
HK Stock
MICROPORT NEURO (02172) spent approximately HK$1.0348 million to repurchase 100,000 shares on April 29th.
HK Stock
Hansoh Pharma (03692): B7-H3 targeted antibody-drug conjugate HS-20093 approved as breakthrough therapy for castration-resistant prostate cancer.
HK Stock
RECOMMEND
China Leads as Humanoid Robotics Reach Commercial Turning Point
China Leads as Humanoid Robotics Reach Commercial Turning Point
icon
29/04/2026
AI Disruption Reshapes US Equity Valuations as Terminal Value Volatility Takes Center Stage
AI Disruption Reshapes US Equity Valuations as Terminal Value Volatility Takes Center Stage
icon
29/04/2026
Political Bureau Meeting Sets Tone for Growth Eight Key Takeaways on Property Capital Markets and Monetary Policy
Political Bureau Meeting Sets Tone for Growth Eight Key Takeaways on Property Capital Markets and Monetary Policy
icon
29/04/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.